A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia

OBJECTIVE: Fludarabine, cyclophosphamide and rituximab (FCR) is the standard regimen for fit patients with untreated CD20-positive chronic lymphocytic leukemia (CLL). However, this combination is unavailable in Japan because rituximab is not approved for CLL. We investigated the efficacy and safety...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Jpn J Clin Oncol
Main Authors: Izutsu, Koji, Kinoshita, Tomohiro, Takizawa, Jun, Fukuhara, Suguru, Yamamoto, Go, Ohashi, Yasuo, Suzumiya, Junji, Tobinai, Kensei
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7937417/
https://ncbi.nlm.nih.gov/pubmed/33244584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyaa215
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados